Consensus Jade Biosciences, Inc.

Stocks

JBIO

US0080642061

Biotechnology & Medical Research

Market Closed - Nasdaq 06:00:00 10/09/26 am AEST			5-day change	1st Jan Change
19.06 ^USD	-2.01%		-9.32%	+23.53%

05:06am	Jade Biosciences, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 09:20 AM
05/09	Climb Bio's Phase-1 Data From IgA Nephropathy Trial 'Positive,' Wedbush Says	MT

Evolution of the Average Target: Jade Biosciences, Inc.

Evolution of the Target Price: Jade Biosciences, Inc.

Changes in Analyst Recommendations: Jade Biosciences, Inc.

585ae51800d.yjKUrgMR1dIYTqGuHV0GOAWCUD5puj4U0dq2OmYxloU.uwOk1G9ko7NOLc3nWDhUVE3mD0Qa6UctpaP5DzwH-u-wV6WdYnaDs1M67A~9a13714caced3035fe28d770fef813fe

Analysts' recommendations: Jade Biosciences, Inc.

05/09	Climb Bio's Phase-1 Data From IgA Nephropathy Trial 'Positive,' Wedbush Says	MT
11/08	Wedbush Adjusts Price Target on Jade Biosciences to $47 From $45, Keeps Outperform Rating	MT
15/06	UBS Initiates Jade Biosciences at Buy With $45 Price Target	MT
02/06	Wedbush Raises Price Target on Jade Biosciences to $45 From $34, Maintains Outperform Rating	MT
08/05	Wedbush Raises Price Target on Jade Biosciences to $34 From $24, Keeps Outperform Rating	MT
08/05	Wedbush Raises Price Target on Jade Biosciences to $34 From $24, Maintains Outperform Rating	MT
09/03	William Blair Initiates Coverage on Jade Biosciences With Outperform Rating	MT
07/01	HC Wainwright Initiates Jade Biosciences at Buy With $25 Price Target	MT
24/12	Wedbush Adjusts Price Target on Jade Biosciences to $24 From $19, Maintains Outperform Rating	MT
15/11	Wedbush Adjusts Price Target on Jade Biosciences to $19 From $18, Maintains Outperform Rating	MT
09/10/25	BTIG Initiates Jade Biosciences at Buy With $28 Price Target	MT
14/08/25	Wedbush Adjusts Price Target on Jade Biosciences to $18 From $17, Maintains Outperform Rating	MT
16/06/25	Guggenheim Upgrades Jade Biosciences to Buy From Neutral, Price Target is $14	MT
05/05/25	Stifel Nicolaus Initiates Coverage on Jade Biosciences With Buy Rating, $19 Price Target	MT
02/05/25	TD Cowen Initiates Coverage on Jade Biosciences With Buy Rating	MT
18/06/24	Guggenheim Downgrades Aerovate Therapeutics to Neutral From Buy	MT
18/06/24	TD Cowen Downgrades Aerovate Therapeutics to Hold From Buy	MT
18/06/24	Evercore ISI Downgrades Aerovate Therapeutics to In Line From Outperform, Adjusts Price Target to $2 From $27	MT
18/06/24	Top Midday Decliners	MT
18/06/24	Jefferies Downgrades Aerovate Therapeutics to Hold From Buy, Cuts Price Target to $2 From $65; Shares Plummet	MT
18/06/24	Wells Fargo Downgrades Aerovate Therapeutics to Equalweight From Overweight, Cuts Price Target to $2 From $35; Shares Plummet	MT
18/06/24	BTIG Downgrades Aerovate Therapeutics to Neutral From Buy	MT
17/06/24	Wedbush Downgrades Aerovate Therapeutics to Neutral From Outperform, Adjusts Price Target to $3 From $41	MT
16/08/23	Wedbush Adjusts Aerovate Therapeutics Price Target to $48 From $50, Maintains Outperform Rating	MT
17/05/23	Wedbush Lowers Aerovate Therapeutics' Price Target to $50 From $54, Keeps Outperform Rating	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	JADE BIOSCIENCES, INC.					+157.71%
	LONZA GROUP AG					+23.77%
	REVOLUTION MEDICINES, INC.					+20.81%
	IQVIA HOLDINGS INC.					+6.58%
	BEONE MEDICINES AG					+22.95%
	CELLTRION, INC.					+46.49%
	ASCENDIS PHARMA A/S					+16.5%
	MEDPACE HOLDINGS, INC.					-1.53%
	EUROFINS SCIENTIFIC SE					+1.46%
	CHARLES RIVER LABORATORIES INTERNATIONAL, INC.					+0.09%
	Average					+29.48%
	Weighted average by Cap.					+19.45%